Skip to main content
Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.410
0.00 (0.00%)
At close: Nov 20, 2024, 4:00 PM
2.400
-0.010 (-0.41%)
Pre-market: Nov 21, 2024, 6:11 AM EST

Esperion Therapeutics Revenue

Esperion Therapeutics had revenue of $51.63M in the quarter ending September 30, 2024, with 52.00% growth. This brings the company's revenue in the last twelve months to $295.45M, up 187.12% year-over-year. In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth.

Revenue (ttm)
$295.45M
Revenue Growth
+187.12%
P/S Ratio
1.36
Revenue / Employee
$1,231,046
Employees
240
Market Cap
474.85M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023116.33M40.86M54.14%
Dec 31, 202275.48M-2.97M-3.79%
Dec 31, 202178.45M-149.10M-65.52%
Dec 31, 2020227.55M79.18M53.37%
Dec 31, 2019148.36M--
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
DocGo 694.97M
Revance Therapeutics 256.95M
Xeris Biopharma Holdings 187.36M
Pacific Biosciences of California 173.15M
National Research 144.16M
Quanterix 129.33M
Aquestive Therapeutics 58.90M
Foghorn Therapeutics 25.52M
Revenue Rankings

ESPR News

More News